• Home
  • About
    • Overview
    • Sharing Data
    • ORCID
  • Help
  • History (47)
    • Plasma kallikrein promotes epidermal growth factor receptor transactivation and signaling in vascular smooth muscle through direct activation of protease-activated receptors.
    • Loganiaceae
    • St. Jude prosthesis for aortic and mitral valve replacement: a ten-year experience.
    • Co-I Project 3 PI, Core B & Core C
    • A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
    • See All 47 Pages
  • search
    • Find People
    • Find Everything
Login to edit your profile (add a photo, awards, links to other websites, etc.)
  • Edit My Profile
  • My Person List (0)

A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.

A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. N Engl J Med. 2019 08 08; 381(6):509-519.

View in: PubMed

subject areas
  • Adolescent
  • Adult
  • Anemia, Sickle Cell
  • Antisickling Agents
  • Benzaldehydes
  • Biomarkers
  • Child
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Therapy, Combination
  • Female
  • Hemoglobin, Sickle
  • Hemoglobins
  • Hemolysis
  • Humans
  • Hydroxyurea
  • Intention to Treat Analysis
  • Male
  • Middle Aged
  • Polymerization
  • Pyrazines
  • Pyrazoles
  • Young Adult

authors with profiles
  • Miguel Raul Abboud